WuXi Biologics pushes Massachusetts factory opening to 2028 after pausing construction in 2024 for a facility redesign.
June 22, 2026 11:40 AM EDTUpdated 01:19 PM
PharmaManufacturing
After 'redesign,' WuXi Biologics sets new timeline for Massachusetts factory completion
Anna Brown
News Reporter
WuXi Biologics' 25th Drug Substance Facility Completes First GMP Production, Manufacturing Process Execution with Zero Deviations
WuXi Biologics' Suzhou Biosafety Testing Center Received Fourth EMA GMP Certification, Enabling 19 Commercial Products for the European Market
WuXi Biologics win overall excellence award at Life Sciences Industry Awards 2026
Quaker Houghton Opens New Manufacturing Site and Expanded Lab in China
Wheeler Bio Launches New Website Reflecting Expansion of Capabilities, Clients Served, and a Commitment to High-Science, High-Touch Biologics Manufacturing
HHS, responding to China’s rise, moves to fast-track early drug research
WuXi Biologics Achieves GMP Release of 18th Drug Product Facility, Advancing Integrated Drug Substance to Drug Product…
WuXi Biologics' 25th Drug Substance Facility Completes First GMP Production, Manufacturing Process Execution with Zero Deviations
WuXi Biologics Receives Brazil ANVISA GMP Certification to Enable Global Commercial Manufacturing of Innovative Cancer…
WuXi Biologics Singapore CRDMO Hub Completes Modular Topping-Out of Drug Product Facility
WuXi Biologics' MFG8 Drug Substance Facility Secures FDA PLI Approval, Advancing Commercial Supply of a Potential Blockbuster…
WuXi Biologics' Suzhou Biosafety Testing Center Received Fourth EMA GMP Certification, Enabling 19 Commercial Products for the…
